Analyst firms · The Benchmark Company · ABCL
The Benchmark Company ABCL price target and rating history
AbCellera Biologics Inc. (ABCL) · Health Care
The Benchmark Company rates AbCellera Biologics Inc. (ABCL) Buy with a $11 price target, as of its latest action on Jul 7, 2026. It has published 6 rating actions on ABCL since December 2021, including 2 upgrades and 2 downgrades. Across 5 firms with a ABCL price target in the last 12 months, the median target is $13. The Benchmark Company's $11 is 15% below that.
- Current rating
- Buy
- Price target
- $11
- Median target, all firms
- $13
- Actions on ABCL
- 6
The Benchmark Company price target on ABCL
Every The Benchmark Company rating on ABCL
- Jul 7, 2026
- Aug 20, 2024
- Feb 22, 2024
- Nov 6, 2023
- Dec 21, 2021
- Dec 21, 2021
How other firms rate ABCL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Lake Street | Buy | $19 | Nov 18, 2026 |
| UBS | Buy | $18 | Oct 12, 2026 |
| Goldman Sachs | Neutral | $13 | Sep 24, 2026 |
| The Benchmark Company | Buy | $11 | Jul 7, 2026 |
| Cantor Fitzgerald | Overweight | $7 | May 5, 2026 |
Questions about The Benchmark Company and ABCL
- What is The Benchmark Company's price target for ABCL?
- The Benchmark Company's latest stated price target for AbCellera Biologics Inc. (ABCL) is $11, from its action on Jul 7, 2026.
- What is The Benchmark Company's rating on ABCL?
- The Benchmark Company rates ABCL Buy, a bullish rating, as of Jul 7, 2026.
- When did The Benchmark Company last change its view on ABCL?
- On Jul 7, 2026, The Benchmark Company upgrades to Buy from Hold, price target $11.
- How does The Benchmark Company's ABCL target compare with other analysts?
- Across 5 firms with a ABCL price target in the last 12 months, the median target is $13. The Benchmark Company's $11 is 15% below that.
More ABCL rating histories
All The Benchmark Company ratingsABCL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.